Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.
来源：PubMed发布日期：2026-05-01作者：Palomba ML, Patel MR, Eyre TA, Jurczak W, Lewis D0 次点击